Keywords: novartis, gets, broader, fda, indication, heart, failure
Novartis gets broader FDA indication, for heart failure, on Diovan
Article | 15 August 2005
The US Food and Drug Administration has approved Swiss pharmaceutical major Novartis' Diovan (valsartan), the most-prescribed angiotensin receptor blocker worldwide, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
